Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NewCardio, a cardiac diagnostic and services company, has appointed Michael Hanson to its board of directors, effective April 1, 2009. With this election, the company's board now includes seven directors, including five independent directors.
Subscribe to our email newsletter
Mr Hanson is a founding partner of Barnard Life Sciences, a healthcare consulting company founded in 2001. From 2004 to 2009, Mr Hanson was a member of the board of directors for compensation and audit committees of Indevus Pharmaceuticals.
Mr Hanson also serves on the board of directors of Z-92 Pharma and Elcos, and is also a member of Pearl Street Ventures, a venture capital firm that specializes in healthcare companies and Cardinal Equity Partners.
Mr Hanson has received a BS in pharmacy from North Dakota State University and an MS in hospital pharmacy administration from the University of Minnesota.
Branislav Vajdic, CEO of NewCardio, said: “Mike adds an impressive amount of relevant industry experience from his 25 years at Eli Lilly and Company and experience as a director for several private as well as publicly traded healthcare and pharmaceutical companies. We are excited to add him to our board of directors and are confident we will benefit from his proven expertise as a healthcare professional, an investment consultant and a public company director.”